IPSC · Century Therapeutics, Inc.

Century Therapeutics’ Q1 2026 financial results reflect a strategic pivot toward internal pipeline advancement following the conclusion of a major collaboration: the $109.2 million collaboration revenue recognized in Q1 2025 did not recur, resulting in a $21.6 million net loss versus prior-year net income. This shift is intentional — management explicitly tied the decline in R&D spend ($17.1M vs. $26.6M) to reduced personnel and lower clinical trial activity, consistent with prioritizing IND-enabling work for CNTY-813 and CNTY-308 over externally funded programs. The $135 million private placement completed in January 2026 directly enabled the $99.9 million sequential increase in cash and marketable securities (to $217.0M), underpinning the company’s stated cash runway into Q1 2029. Operationally, progress is concentrated on two near-term catalysts: CNTY-813’s IND submission in Q4 2026 — supported by completed GMP Master Cell Bank manufacturing, compelling preclinical data on glucose control and immune evasion, and recent FDA engagement — and CNTY-308’s planned clinical initiation in 2026. Management’s commentary emphasizes disciplined execution of its Allo-Evasion™-enabled iPSC platform to deliver off-the-shelf therapies, with the ADA oral presentation on June 8, 2026 serving as a key near-term scientific validation point. No forward financial guidance was provided beyond the cash runway estimate; all development timelines remain subject to regulatory clearance and completion of remaining studies.